|
Marcus' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: The FDA is nearing a decision on BridgeBio’s muscular dystrophy therapy, while Estuary raises $93 million for kidney gene therapy and Wnt-targeting cancer data emerge.
The top 10 stories from Fri Oct 30, 2026 06:51 AM to Mon Nov 2, 2026 06:47 AM
Generated November 2, 2026 at 6:47 AM
|
|
|
#1 What made Estuary’s kidney gene therapy bet investable Published 2026-10-30 Estuary raised $93 million in Series A funding to develop a one-time gene therapy for autosomal dominant polycystic kidney disease, amid competition from other treatment approaches. Covered by: biocentury.com |
#2 Once undruggable, the Wnt/B-catenin pathway shows increasing promise Published 2026-10-30 Early clinical data from several companies suggest the Wnt/β-catenin pathway may offer a treatment target across multiple cancer types. Covered by: biospace.com |
#3 BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight Published 2026-11-02 The FDA is expected to decide by Nov. 27 whether to approve BridgeBio Pharma’s BBP-418, which could become the first therapy for limb-girdle muscular dystrophy. Covered by: biospace.com |
#4 Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System Published 2026-11-01 Abbott reported strong 30-day outcomes and high procedural success in the TECTONIC trial of its investigational SonicForce coronary lithotripsy system. Covered by: prnewswire.com |
#5 Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. Published 2026-10-31 Zhimeng Biopharma completed patient enrollment in the pivotal Phase 2/3 trial of its investigational ALS drug, CB03-154. Covered by: prnewswire.com |
#6 FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis Published 2026-10-30 The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis. Covered by: fda.gov, prnewswire.com |
#7 Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back Published 2026-10-30 Gilead paused a CAR-T program after several cases of ICANS, while the FDA delayed Agios’ PDUFA date. Covered by: endpoints.news |
#8 StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance Published 2026-11-01 Gene-editing stocks rose after positive data at a European industry congress and FDA draft guidance outlining a pathway for personalized genome-editing therapies for rare diseases. Covered by: genengnews.com |
#9 New clinical data on lecanemab to be presented at CTAD conference 2026 Published 2026-10-30 Eisai will present new clinical and real-world evidence on lecanemab at the Clinical Trials on Alzheimer’s Disease conference in Boston, November 16–19, 2026. Covered by: prnewswire.com, prnewswire.com |
#10 No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT Published 2026-10-30 At ESGCT 2026, David Liu highlighted progress combining AI, prime editing and advances in regulation, manufacturing and economics to expand genome editing beyond rare genetic diseases. Covered by: genengnews.com |
